# US 2013/0295100 A1 · Markers for acute kidney injury and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0295100 A1
- Document ID: US20130295100A1
- Status: Published application
- Kind: A1
- Application number: 13/988,437
- Filed: 2011-11-21
- Published: 2013-11-07
- Earliest claimed: 2010-11-19
- Assignees: Ospedale San Raffaele S.R.L.
- Inventors: Paolo Manunta; Lorena Citterio; Giovanni Guglielmo Landoni; Elena Giovanna Bignami; Elisabetta Messaggio
- Web page: https://patentgrep.com/patent/US20130295100A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a method for predicting the risk of developing acute kidney injury in a subject from which a biological sample is obtained comprising: detecting the presence of at least one genomic single nucleotide polymorphism (SNP) selected from the group of: ADD1 rs4961 Trp [allelic genotype GT or TT], ADD2 rs4984 [allelic genotype CT or TT], HS-D3B1 rs2236780 [allelic genotype GG], LSS rs914247 [allelic genotype AA], MDR1 rs1045642 [allelic genotype TC or CC], SLC8A1 rs1 1893826 [allelic genotype AA], TRPC6 rs7925662 [allelic genotype CC] from said biological sample, wherein the presence of said allelic genotype is predictive of the risk of developing acute kidney injury.

## Claims

### Claim 1

A method for predicting the risk of developing acute kidney injury in a subject from which a biological sample is obtained, said method comprising:
detecting the presence of at least one genomic single nucleotide polymorphism (SNP) selected from the group consisting of:
ADD1 rs4961 Trp [allelic genotype GT or TT],
ADD2 rs4984 [allelic genotype CT or TT],
HSD3B1 rs2236780 [allelic genotype GG],
LSS rs914247 [allelic genotype AA],
MDR1 rs1045642 [allelic genotype TC or CC],
SLC8A1 rs11893826 [allelic genotype AA], and
TRPC6 rs7925662 [allelic genotype CC] from said biological sample,
wherein the presence of said allelic genotype is predictive of the risk of developing acute kidney injury.

### Claim 2 (depends on 1)

The method according to claim 1 further comprising measuring the level of endogenous ouabain in a biological sample, wherein a level greater than 207 pM is predictive of the risk of developing acute kidney injury.

### Claim 3 (depends on 1)

The method according to claim 1 wherein the presence of at least two genomic single nucleotide polymorphisms SNPs is detected.

### Claim 4 (depends on 3)

The method according to claim 3 wherein the two genomic SNPs are:
ADD2 rs4984 [allelic genotype CT or TT] and HSD3B1 rs2236780 [allelic genotype GG];
ADD2 rs4984 [allelic genotype CT or TT] and SLC8A1 rs11893826 [allelic genotype AA];
LSS rs914247 [allelic genotype AA] and SLC8A1 rs11893826 [allelic genotype AA]; or
TRPC6 rs7925662 [allelic genotype CC] and ADD1 rs4961 Trp [allelic genotype GT or TT].

### Claim 5 (depends on 2)

The method according to claim 2 wherein the genomic SNP is MDR1 rs1045642 [allelic genotype TC or CC].

### Claim 6 (depends on 1)

The method according to claim 1 wherein the biological sample is a biological fluid or a tissue.

### Claim 7 (depends on 2)

The method according to claim 2 wherein the level of endogenous ouabain is measured by scintillation proximity assay.

### Claim 8 (depends on 1)

The method according to claim 1 to predict the risk of developing acute kidney injury after stress.

### Claim 9 (depends on 8)

The method according to claim 8 wherein the stress is an acute hemodynamic stress.

### Claim 10 (depends on 8)

The method according to claim 8 wherein the stress is caused by a surgery.

### Claim 11 (depends on 10)

The method according to claim 10 wherein the surgery is a cardiac or vascular surgery.

### Claim 12 (depends on 1)

A kit for predicting the risk of developing acute kidney injury according to the method of claim 1 comprising reagents to detect at least one single nucleotide polymorphism (SNP) selected from the group consisting of:
ADD1 rs4961 Trp [allelic genotype GT or TT],
ADD2 rs4984 [allelic genotype CT or TT],
HSD3B1 rs2236780 [allelic genotype GG],
LSS rs914247 [allelic genotype AA],
MDR1 rs1045642 [allelic genotype TC or CC],
SLC8A1 rs11893826 [allelic genotype AA], and
TRPC6 rs7925662 [allelic genotype CC].

### Claim 13 (depends on 12)

The kit according to claim 12 comprising reagents to detect at least one combination of SNPs selected from the group consisting of:
ADD2 rs4984 [allelic genotype CT or TT] and HSD3B1 rs2236780 [allelic genotype GG];
ADD2 rs4984 [allelic genotype CT or TT] and SLC8A1 rs11893826 [allelic genotype AA];
LSS rs914247 [allelic genotype AA] and SLC8A1 rs11893826 [allelic genotype AA]; and
TRPC6 rs7925662 [allelic genotype CC] and ADD1 rs4961 Tip [allelic genotype GT or TT]

### Claim 14 (depends on 12)

The kit according to claim 12 further comprising means to measure endogenous ouabain level.

### Claim 15 (depends on 14)

The kit according to claim 14 comprising reagents to detect the SNP MDR1 rs1045642 [allelic genotype TC or CC] and means to measure endogenous ouabain level.

### Claim 16 (depends on 1)

A selective ouabain inhibitor for use to decrease the risk of developing AKI in a subject at risk of developing AKI predicted according to the method of claim 1.

### Claim 17 (depends on 16)

The selective ouabain inhibitor according to claim 16 being rostafuroxin or digibind.

### Claim 18 (depends on 1)

A method for decreasing the risk of developing AKI in a subject comprising:
predicting the risk of developing AKI according to claim 1; and
if the subject is at risk, administering to said subject a selective endogenous ouabain inhibitor.

### Claim 19 (depends on 18)

The method according to claim 18 wherein the selective endogenous ouabain inhibitor is rostafuroxin or digibind.
